Addiction researchers are testing a suite of experimental drugs on human volunteers to see if they can weaken the core behavioural drives behind heroin, cocaine, and alcohol dependence. Most addiction treatments have been discovered by accident or repurposed from other conditions. This project aims to replace that trial-and-error approach with a rational, biology-driven method. The ICCAM cluster—a collaboration between Imperial College London, Cambridge, and Manchester—has already identified several promising drug candidates based on the brain circuits and chemical signals that underpin addiction. Now they need a fast, standardised way to test these drugs in people. The team will build a “platform” that works identically across all three sites. Volunteers will take candidate drugs and then undergo brain scans while performing tasks that involve reward, impulse control, and craving. The scans will reveal whether the drug dampens the brain’s addiction-related activity. Neuropsychological tests and follow-up clinical monitoring will confirm whether those brain changes translate into real-world reductions in drug use. If the platform proves reliable, it could accelerate the screening of new addiction treatments from years to months. That would give clinicians a faster pipeline of evidence-based drugs for a condition that currently has few effective pharmacological options.
View original technical description
Addiction to drugs such as heroin, cocaine and alcohol are a major problem in our society and globally. Is it possible to understand the processes that lead to addiction and to develop drugs that can be used for treatment? These are the two major questions that motivate the ICCAM addictions research cluster and this application. The ICCAM cluster brings together clinical and preclinical researchers from Imperial College London, Cambridge and Manchester Universities to address the problem of drug development for addiction. We seek to identify rational potential targets for drug development based upon our understanding of the pharmacology and brain processes engaged in addiction, rather than a random ?shotgun? approach. As a society, many think of addiction to drugs such as heroin, cocaine and alcohol as individual conditions with underlying social causes. This may not be the case with the established clinical condition, and this point of view may have impeded rational drug development for these disorders. The ICCAM cluster has identified multiple potential therapeutic drugs that may be of use in the treatment of addiction and now seeks to develop a ?platform? to rapidly assess their efficacy in humans. The word ?platform? means that we will adopt a common research approach based at each of our three sites to study the effects of particular drugs in human participants on processes that are relevant to addiction. We will use state of the art brain imaging techniques to study the effect of drugs on brain activity while a person responds to rewards, for example. These will be combined with neuropsychological assessment and monitoring of clinical outcomes to develop our research capacity.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know